Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome by Tesauro, Manfredi et al.
Tumor Necrosis Factor- Antagonism
Improves Vasodilation During
Hyperinsulinemia in Metabolic Syndrome
MANFREDI TESAURO, MD
1
FRANCESCA SCHINZARI, MD
2
VALENTINA ROVELLA, MD
1
DOMENICO MELINA, MD
2
NADIA MORES, MD
2
ANGELA BARINI, MD
2
MARCO METTIMANO, MD
2
DAVIDE LAURO, MD
1
MICAELA IANTORNO, MD
3
MICHAEL J. QUON, MD, PHD
3
CARMINE CARDILLO, MD
2
OBJECTIVE — Obesityisassociatedwithchronicinﬂammationduetooverproductionof
proinﬂammatory cytokines, including tumor necrosis factor (TNF)-. We assessed the
effectsofTNF- neutralizationbyinﬂiximabonvascularreactivityduringhyperinsulinemia
in obesity-related metabolic syndrome.
RESEARCH DESIGN AND METHODS — Vascular responses to intra-arterial infusion
ofacetylcholine(ACh)andsodiumnitroprusside(SNP)wereassessedinpatientswithmetabolic
syndrome, before and after administration of inﬂiximab.
RESULTS — Patients had blunted vasodilator responses to ACh and SNP during hyperinsu-
linemia compared with control subjects; a potentiation of the responsiveness to both ACh and
SNP, however, was observed in patients following inﬂiximab. The antioxidant vitamin C im-
proved the vasodilator response to ACh in patients with metabolic syndrome, but its effect was
not further enhanced by concurrent administration of inﬂiximab.
CONCLUSIONS — TNF- neutralization ameliorates vascular reactivity in metabolic syn-
dromeduringhyperinsulinemia,likelyinrelationtodecreasedoxidativestress,therebysuggest-
ing an involvement of inﬂammatory cytokines in vascular dysfunction of these patients.
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C
entralobesityisassociatedwithlow-
grade, chronic inﬂammation, which
might affect insulin action and thus
contribute to both insulin resistance and
vascular dysfunction characteristic of
metabolic syndrome. Among various
inﬂammatorycytokines,tumornecrosis
factor (TNF)- seems to play an impor-
tant role in the pathophysiology of in-
sulin resistance. However, no clear link
hasbeenestablishedbetweenthevascu-
lar pathology of metabolic syndrome
and a particular inﬂammatory cytokine
in humans. This study, therefore, as-
sessed the effects of TNF- neutralization
by the monoclonal antibody inﬂiximab on
vascular reactivity during hyperinsulin-
emia in metabolic syndrome.
RESEARCH DESIGN AND
METHODS— A total of 16 patients
with metabolic syndrome (National Cho-
lesterol Education Program Adult Treat-
ment Panel [NCEP ATP] III criteria) and
13 healthy control subjects, approxi-
mately matched for sex and age, were re-
cruitedforthisstudy.Inallpatients,waist
circumferencewas102cminmalesub-
jects and 88 cm in female subjects, thus
indicating central obesity. Studies con-
sisted of infusion of drugs into the bra-
chial artery and measurement of forearm
blood ﬂow responses by means of strain-
gauge plethysmography. In Study 1, con-
trol subjects and 10 patients with
metabolic syndrome received infusion of
regular insulin (0.2 mU   kg
1   min
1);
after 45 min of insulin infusion, dose-
responsecurvestogradeddosesofacetyl-
choline (ACh) (release of endogenous
NO)andsodiumnitroprusside(SNP)(ex-
ogenous NO donor) were obtained.
Thereafter,whilekeepinginsulininfusion
constant, patients with metabolic syn-
drome received infusion of inﬂiximab
(200 g/min for 45 min) and dose-
response curves to ACh and SNP were re-
peated. In Study 2, to assess whether the
effect of inﬂiximab on vascular response
to ACh might relate to reduction of oxi-
dative stress, six additional patients with
metabolic syndrome underwent a ﬁrst
dose-response curve to ACh during hy-
perinsulinemiaalone.VitaminCwasthen
given at 25 mg/min for 45 min and a sec-
ond dose-response curve to ACh was ob-
tained. Finally, inﬂiximab infusion was
superimposed and a third dose-response
curve to ACh was obtained during con-
current administration of vitamin C and
inﬂiximab. Statistical analyses were per-
formed by t test and ANOVA, as appro-
priate. Data are reported as mean  SEM
and P  0.05 was considered statistically
signiﬁcant.
RESULTS— Patients had higher
blood pressure (P  0.001), plasma cho-
lesterol (P  0.05), triglycerides (P 
0.05), and glucose (P  0.01) than con-
trolsubjects.Baselineinsulinwaslowerin
control subjects than in patients (6.2 
1.5 vs. 11.3  1.7 U/ml, respectively;
P  0.03); following insulin administra-
tion, venous insulin concentration in the
perfusedforearmroseto17137incon-
trolsubjectsversusto22432U/mlin
patients (P  0.44).
The vasodilator response to ACh was
blunted in patients compared with con-
trol subjects (12.7  1.4 vs. 26.5  3.1
ml   min
1   dl
1 at the highest dose of
ACh, respectively; P  0.001). Similarly,
thevasodilatorresponsetoSNPwaslower
in patients than in control subjects
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1  
dl
1,respectively;P0.001).Inpatients
with metabolic syndrome participating in
Study 1, inﬂiximab improved the vasodi-
lator response to both ACh (Fig. 1A) and
SNP (Fig. 1B). In patients participating in
Study 2, vascular response to ACh was
signiﬁcantly enhanced by administration
of vitamin C compared with hyperinsu-
linemia alone (Fig. 1C); under those con-
ditions, however, infusion of inﬂiximab
in conjunction with vitamin C did not
modify vascular responsiveness to ACh
versus vitamin C alone (Fig.1D).
CONCLUSIONS — This study pro-
vides the novel ﬁnding that TNF- neu-
tralization improves NO-dependent
vasodilation during hyperinsulinemia,
thereby suggesting that TNF- activation
is involved in vascular dysfunction of
metabolic syndrome.
Overexpression of TNF- has previ-
ously been reported not only in obese ad-
ipose tissue (1) and in the skeletal muscle
of insulin-resistant animals and humans
(2), but also in vascular smooth muscle
cells (VSMCs) (3). The decreased respon-
siveness to both endothelium-dependent
and-independentstimuliseenduringhy-
perinsulinemia in our patients, taken in
conjunction with the favorable effect of in-
ﬂiximab on responses to both ACh and
SNP,suggeststhatTNF-activationinmet-
abolic syndrome affects NO-dependent
vasodilation through mechanisms other
than endothelial dysfunction. This phe-
nomenonmightbedeterminedbyimpaired
insulinsignalingwithinVSMCs,thusaffect-
ing the facilitatory action physiologically
exerted by insulin on vasorelaxation. This
hypothesisstemsfromstudiesshowingthat
insulin may impact VSMCs’ vasodilator ca-
pacity through multiple mechanisms. In
particular, impairment of insulin inactiva-
tionofthesmallGTPaseRhoAanditstarget
-kinase, leading to decreased vasodilation,
has been reported in VSMCs from insulin-
resistant animals (4). Because this defect lo-
calizes at the same level of PI3-kinase acti-
vation (5) at which TNF- upregulation
affects insulin signaling (6), the vascu-
lar effect of TNF- antagonism ob-
served in our patients is consonant with
restoration of the facilitatory role of in-
sulin on VSMCs relaxation.
Recent experimental evidence indi-
cates that TNF- overexpression in-
creases oxidative stress (7) and that TNF-
–induced reactive oxygen species play a
causal role in insulin resistance (8). We
testedthepossibilitythatincreasedoxida-
tive stress could also be involved in hu-
man TNF- vasculopathy by use of
vitamin C. This antioxidant improved the
vasodilator response to ACh during hy-
perinsulinemia in metabolic syndrome,
whereas inﬂiximab infusion on top of vi-
tamin C did not exert additive effects.
This suggests that increased oxidative
stress is indeed involved in mediating the
effects of TNF- on vasodilation during
hyperinsulinemia, a view supported by
previous results showing that reactive ox-
ygen species could affect vascular reactiv-
ity through changes in receptor function
or activity of signaling pathways (9,10).
The beneﬁcial action of inﬂiximab
demonstrated in our study suggests a
novel mechanism by which TNF- acti-
vation might be involved, via increased
oxidative stress, in vascular dysfunction
of patients with obesity-related metabolic
syndrome; it remains to be elucidated
whetherinterventionstargetingcytokines
may become an effective strategy for pre-
vention in these patients.
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